Healthcare Costs Prevented Almost 40 Million Americans from Filling Their Prescriptions in 2008

Manhattan ResearchNearly 40 million U.S. adults decided not to fill a prescription medication from a doctor in the past year because of the cost, according to pharmaceutical and healthcare market research company Manhattan Research’s Cybercitizen Health™ v8.0 consumer study and strategic advisory service. The study found that women and patients with neurological and mental health conditions were the most likely to give up their medication due to cost.

For those struggling to afford healthcare, online channels have become increasingly important resources. Over 145 million consumers are online for health, and this year's Cybercitizen Health™ study saw the Internet surpass doctors as the top source for obtaining health and medical information.

Top Condition Groups Who Report Not Filling a Prescription Because of the Cost

1. Fibromyalgia
2. Inflammatory Bowel Disease
3. Generalized Anxiety Disorder
4. Chronic Bronchitis
5. Chronic Pain
6. Acute Pain
7. Adult ADHD
8. Anxiety Disorder/Social Phobia
9. Bipolar Disorder
10. Depression
Among U.S. adults (18+)
Source: Cybercitizen Health™ v8.0 (2008)

"Healthcare costs and accessibility are major barriers for Americans, and many are turning to the Internet as an alternative resource for managing their health and making treatment decisions," said Meredith Abreu Ressi, Vice President of Research at Manhattan Research. "While the Internet is an invaluable health resource for patient education and support, it doesn't replace the expertise of a trained medical professional. Healthcare providers, pharmaceutical companies, and other organizations can use online media to inform consumers of the importance of professional medical attention to their long-term health and to raise awareness of patient assistance programs."

Complimentary "State of eHealth" Report
For those interested in learning the latest trends of consumers using the Internet for health, Manhattan Research offers its "State of eHealth" report. Topics include the evolving consumer media mix, search engines for health information, and patients engaging in Health 2.0. To access the report, visit http://www.manhattanresearch.com/research/white-papers/state-of-ehealth.aspx

About Cybercitizen Health™ v8.0
Cybercitizen Health™ v8.0 was fielded in Q3 2008 among 8,714 U.S. adults (ages 18+). This consumer market research and strategic advisory service focuses on how consumers use new media and technology for health and its impact on treatment and product decisions. For topics and available therapeutic segmentations (100+), visit http://www.manhattanresearch.com/cch

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a leading market research and advisory services firm for global pharmaceutical and healthcare companies. For more information, visit http://www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

Most Popular Now

Johnson & Johnson announces advance purchase a…

Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has entered into an agreement with the African Vacci...

Pfizer and BioNTech confirm high efficacy and no s…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced updated topline results from analysis of 927 confirmed symptomatic cases of COVID-19 observed in their pi...

Pfizer-BioNTech announce positive topline results …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, in a Phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence of SAR...

GSK to support manufacture of Novavax' COVID-19 va…

GSK has reached an agreement in principle with Novavax and the UK Government Vaccines Taskforce to support manufacturing of up to 60 million doses of Novavax' COVID-19 va...

Valneva reports positive Phase 1/2 data for its in…

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical n...

Clinical trial completion rates decline during COV…

Social distancing and lockdowns may have reduced the spread of COVID-19, but researchers from Penn State College of Medicine also report those actions may have affected c...

BioNTech provides update on vaccine production sta…

BioNTech SE today announced that the European Medicines Agency (EMA) approved the manufacturing of the COVID-19 vaccine drug product at the facility in Marburg. As part o...

COVID-19 convalescent plasma with greater antibody…

Convalescent plasma, the use of survivors' antibodies transfused into sick COVID-19 patients is safe and significantly improves clinical outcomes when using high levels o...

Pfizer and BioNTech request regulatory agencies ex…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today requested amendments to the U.S. Emergency Use Authorization (EUA) of the Pfizer-BioNTech vaccine (BNT162b2) ...

COVID-19 causes 'unexpected' cellular response in …

New insights into the immune response to SARS-CoV-2 infections could bring better treatments for COVID-19 cases. An international team of researchers unexpectedly foun...

Study identifies possible COVID-19 drugs - includi…

A team led by scientists in the Perelman School of Medicine at the University of Pennsylvania has identified nine potential new COVID-19 treatments, including three that ...

Undetected coronavirus variant was in at least 15 …

A highly contagious SARS-CoV-2 variant was unknowingly spreading for months in the United States by October 2020, according to a new study from researchers with The Unive...